- Home
- WFC vs AZN Comparison
WFC vs AZN Comparison
Compare WFC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFC
- AZN
- Stock Information
- Founded
- WFC 1852
- AZN 1992
- Country
- WFC United States
- AZN United Kingdom
- Employees
- WFC N/A
- AZN N/A
- Industry
- WFC Major Banks
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- WFC Finance
- AZN Health Care
- Exchange
- WFC Nasdaq
- AZN Nasdaq
- Market Cap
- WFC 261.0B
- AZN 252.9B
- IPO Year
- WFC N/A
- AZN 1993
- Fundamental
- Price
- WFC $80.67
- AZN $85.31
- Analyst Decision
- WFC Buy
- AZN Strong Buy
- Analyst Count
- WFC 15
- AZN 1
- Target Price
- WFC $84.04
- AZN N/A
- AVG Volume (30 Days)
- WFC 14.0M
- AZN 4.9M
- Earning Date
- WFC 10-14-2025
- AZN 11-11-2025
- Dividend Yield
- WFC 2.23%
- AZN 1.80%
- EPS Growth
- WFC 19.49
- AZN 28.86
- EPS
- WFC 5.82
- AZN 5.31
- Revenue
- WFC $77,618,000,000.00
- AZN $56,501,000,000.00
- Revenue This Year
- WFC $7.81
- AZN $10.87
- Revenue Next Year
- WFC $4.68
- AZN $6.12
- P/E Ratio
- WFC $13.85
- AZN $31.87
- Revenue Growth
- WFC N/A
- AZN 15.00
- 52 Week Low
- WFC $54.41
- AZN $61.24
- 52 Week High
- WFC $86.66
- AZN $85.50
- Technical
- Relative Strength Index (RSI)
- WFC 43.33
- AZN 69.05
- Support Level
- WFC $80.04
- AZN $72.90
- Resistance Level
- WFC $85.64
- AZN $84.61
- Average True Range (ATR)
- WFC 1.74
- AZN 1.43
- MACD
- WFC -0.45
- AZN 0.85
- Stochastic Oscillator
- WFC 9.52
- AZN 99.12
About WFC Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance-sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.